Drug profile · INN
nalmefene hydrochloride
REVEX
nalmefene hydrochloride (REVEX) is an FDA-listed pharmaceutical active ingredient. Associated with Indivior Pty Ltd. Route of administration: intramuscular, subcutaneous. Current US regulatory status: approved.
Drug details — nalmefene hydrochloride
- US status
- approved
- Class
- —
- Route
- INTRAMUSCULAR, SUBCUTANEOUS
- Patents
- 4
- Programs
- 1
- Data quality
- 0.89
Quick answer
nalmefene hydrochloride (REVEX) is an FDA-listed pharmaceutical active ingredient. Associated with Indivior Pty Ltd. Route of administration: intramuscular, subcutaneous. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related patents
-
US 12290596
Compositions and methods for the treatment of opioid overdose
granted -
US 10584135
Substituted 3,6-diazabicyclo[3.2.0]heptanes
granted -
US 10149912
Dehydrated hydrogel inclusion complex
granted -
US 9486531
Dehydrated hydrogel inclusion complex of a bioactive agent with flowable drug delivery system
granted
Frequently asked questions
What is nalmefene hydrochloride?
nalmefene hydrochloride (REVEX) is an FDA-listed pharmaceutical active ingredient. Associated with Indivior Pty Ltd. Route of administration: intramuscular, subcutaneous. Current US regulatory status: approved.
What is the brand name for nalmefene hydrochloride?
REVEX is a marketed brand name for nalmefene hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nalmefene hydrochloride?
nalmefene hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.